Suprachoroidal Triamcinolone Acetonide Injection to Treat Macular Edema: A Review

Purpose: To review the available literature on the efficacy and safety of suprachoroidal triamcinolone acetonide for the treatment of chorioretinal diseases. Methods: The results of a literature review were analyzed. Results: This review included 17 clinical studies of triamcinolone acetonide administration (6, diabetic macular edema; 1, central retinal vein occlusion [RVO]; 2, branch RVO; 7, noninfectious uveitis; 1, cystoid macular edema after cataract surgery). Overall, suprachoroidal triamcinolone acetonide was shown to be effective in decreasing macular thickness and increasing visual acuity (VA) in cases of chorioretinal diseases. The most frequently reported adverse events were eye pain, cataract, and increased intraocular pressure. Conclusions: Except for 3 sufficiently powered trials of suprachoroidal triamcinolone acetonide for macular edema associated with noninfectious uveitis, most other studies were clinical trials with small samples. These studies found that suprachoroidal triamcinolone acetonide has a satisfactory safety and efficacy profile. Further research with sufficiently large samples is required to confirm the potential role of suprachoroidal triamcinolone acetonide in retinal diseases.